Acetohydroxamic acid, to treat struvite uroliths, 92
Allopurinol-induced xanthine uroliths. See Xanthine uroliths, allopurinol-induced.
Ammonium acid urate uroliths, canine, medical dissolution of, 188–189
Ammonium urate nephroliths, canine, 233
Ampicillin, crystalluria associated with, 263
Anesthesia, for voiding urohydropropulsion, 286
Antimicrobics, sulfonamide. See Sulfonamides.

Bladder stones, extracorporeal shock-wave lithotripsy in, 300–301

Calcium oxalate nephroliths, canine, 232–233
Calcium oxalate urolithiasis, canine, 123–139
and struvite urolithis, recurrence of, minimizing of, 105
case study of, 124–125
preventive therapy in, length of time for, 137–138
therapy in, monitoring response to, 136–137
Calcium oxalate uroliths, canine, and concurrent diseases, 119
and struvite uroliths, changing prevalence of, 24–28
elimination of, options for, 126–127
epidemiology of, 113–122
familial patterns of, 114
formation of, reasons for, 125–126
gender and age factors in, 114–115
prevention of, struvite stone formation during, 138

reciprocal relationship between, 119–120
recurrence of, minimizing of, 127–136
role of diet in, 115–118
Calcium phosphate uroliths, canine, case report of, 152–156
etiopathogenesis of, 144–150
management of, recommendations for, 158–159
medical management of, 150–152
mineral composition of, 142–144
prevalence of, 142
prevention of, 150–152
Canine urolithiasis. See Urolithiasis, canine.
Cats, and dogs, nephrolithiasis in, 231–250
extracorporeal shock-wave lithotripsy for treatment of, 301
Contrast agents, radiopaque, crystalluria associated with, 263–265
Crystalluria, drug-associated, 261–265
Crystals, definition of, 18–19, 20
Cystine nephroliths, canine, 234
Cystine urolithiasis, canine, 193–211
amino aciduria and, 197–198, 199–201
biological behavior of uroliths in, 198–199
diagnosis of, 199–202
etiopathogenesis of, 196–198
location of, 196
medical dissolution of uroliths in, 202–209
mineral composition and architecture of uroliths in, 195, 196, 197
nonsurgical removal of uroliths in, 209
prevalence of, 193–195
prevention of, 209
Cystocentesis, decompressive, for canine retrograde urohydropropulsion, 268–270
Cystography, double contrast, in canine urosycoliths, 68–69
Diet(s), as factor in development of urate uroliths, 166–167
for management of struvite uroliths, 90–91
for management of urate uroliths in mature dogs, 189–190
low-purine alkalinizing, in urate uroliths in immature dogs, 190–191
modification of, in calcium oxalate urolithiasis, 132–134, 135
in cystine uroliths, 204
in sterile struvite uroliths, 94
role of, in canine calcium oxalate uroliths, 115–118
Dogs, and cats, nephrolithiasis in, 231–250
urolithiasis in. See Urolithiasis, canine.

Electrohydraulic shock-wave lithotripsy, 293–302
Extracorporeal shock-wave lithotripsy, 293–302

Fluoroquinolones, induction of urolithiasis by, 255

Hypercalciuria, normocalcemic, uroliths associated with, 148–149, 151
Hyperparathyroidism, primary, uroliths associated with, 146–147

Infection, struvite uroliths induced by, biological behavior of, 86–87
management of, 89–94

Lithotomy, 1–3
Lithotripsy, shock-wave. See Shock-wave lithotripsy.

Nephrocalcin, in calcium oxalate urolithiasis, 120–121
Nephroliths, medical dissolution of, 237–238
Nephrolithiasis, canine and feline, 231–250
biological behavior of nephroliths in, 234–235
clinical manifestations of, 235–237
frequency of occurrence of, 231–232
mineral composition and types of, 232–234
treatment of, 237–241
case report illustrating, 241–249

Pneumocystography, in canine urocrystoliths, 67–68
Primidone, induction of urolithiasis by, 255

Radiopaque contrast agents, crystalluria associated with, 263–265
Renal tubular acidosis, distal, uroliths associated with, 148, 151
Retrograde urohydropropulsion, canine. See Urohydropropulsion, canine retrograde.

Shock-wave lithotripsy, electrohydraulic, 293, 294–298
and extracorporeal, 293–302
extracorporeal, 294, 298–300
and electrohydraulic, 293–302
for treatment of cats, 301
in treatment of bladder stones, 300–301
in treatment of ureteroliths, 300
Silica, inorganic, 213–214
organic, 214
Silica nephroliths, canine, 234
Silica urolithiasis, canine, 213–230
biological behavior of uroliths in, 226
detection of, 226–227
epidemiology of, 214–215
etiopathogenesis of, 219–226
mineral composition and architecture of uroliths in, 215–219, 220, 221, 222
recurrent, prevention of, 227–229
Silica uroliths, canine, medical management of, 227
induction of, sources of, 255
Struvite nephroliths, canine, 233
Struvite urolithiasis, canine, and calcium oxalate urolithiasis, recurrence of, 105
biological behavior of, 86–88
common characteristics of, 109–110
current prevalence of, 74, 75
etiopathogenic factors in, 75–86
management of, precautions in patients with concomitant illnesses, 102–103
medical dissolution of, 110–111
and prevention of, 73–111
recurrence of, minimizing of, 103–104
Struvite uroliths, canine, and calcium oxalate uroliths, changing prevalence of, 24–28
infection-induced, treatment of, 3–4
medical management of, current recommendations for, 88–103
recurrence of, minimizing of, 103–104
sterile, management of, 94–95
Sulfonamides, crystalluria associated with, 261–263
induction of urolithiasis by, clinical relevance of, 253–255
epidemiology of, 253
risk factors for, 252–253

Tetracycline, induction of urolithiasis by, 256
Thiol-containing drugs, in cystine urolithiasis, 204–208

Ultrasoundography, real-time, in canine urocystoliths, 69–70
Urate urolithiasis, canine, 161–191
biological behavior of, 169–170
diagnosis of, 167–169
etiopathogenesis and risk factors for, 162–167
terminology associated with, 184–187
Urate uroliths, ammonium acid, canine, medical dissolution of, 188–189
medical dissolution of, 170–176
monitoring response to, 176–178
prophylactic therapy in, 178–179
surgical and medical combination therapy in, 176
Ureteroliths, extracorporeal shock-wave lithotripsy in, 300
Urethra, obstruction by urolith, effectiveness of voiding urohydropropulsion during, 285–286
Urethral catheterization, for temporary bypass of urethroliths, 278–279
to dislodge urethroliths, 279–281
Urethroliths, lubrication of, for canine retrograde urohydropropulsion, 270
palpation of, for canine retrograde urohydropropulsion, 271
urethral catheterization for temporary bypass of, 278–279
urethral catheterization to dislodge, 279–281
Urinalysis, in cystine urolithiasis, 196, 199, 200, 201

Urinary tract, pain and trauma to, canine retrograde urohydropropulsion minimizing, 277–278
Urine, alkalinization of, in cystine urolithiasis, 208–209
Urocystoliths, canine, architectural characteristics of, 61–67
breed predisposition for, 60–61
detection of, techniques of, 67–70
epidemiological background of, 60–61
gender and age incidence of, 61
imaging of, 59–72
integrated approach to, 70–71
size, passing through urethra, determination of, 283–284
Urohydropropulsion, canine retrograde, decompressive cystocentesis for, 268–270
failure of, causes of, 269
lubrication of urethroliths for, 270
major steps for, 267–268
minimizing pain and trauma to urinary tract, 277–278
palpation of urethroliths for, 271
technique of, 271–277
verification and localization for, 268
voiding, 283–291
and urolith removal surgery, time between, 290
anesthesia for, 286
complications associated with, 289
effectiveness of, during obstruction of urethra by urolith, 285–286
urine in bladder lumen to enhance, 284–285
in large dogs, 286
in male dogs, 286
in recurrent urolithiasis, 290
learning to perform, 290
medical shrinking of urolith prior to, 286–287
uroliths lodged in urethra during, management of, 287–289

Urolithiasis, canine, 1–302
calcium oxalate. See Calcium oxalate urolithiasis, canine.
struvite. See Struvite canine urolithiasis.
definition of, 17
drug-induced, 251–266
recurrent, voiding urohydropropulsion in, 290
risk and protective factors for, 39–43
identification of, 40
interpretation for patient care, 40–42
reasons for, 40
study of, future directions in, 52
Urolith(s), allopurinol-induced xanthine. See Xanthine uroliths, allopurinol-induced.
Urolith(s) (Continued)
calcium oxalate canine. See Calcium oxalate uroliths, canine.
canine, analysis of 77,000, 17–38
epilogue concerning, 16
formation of, 45–49
assessment of, 49–52
gross anatomical components of, 21–22
history of management of, 2–3
medical dissolution and prevention of, 1–16
mineral composition of, 20–21, 22
importance of, 31–34
mineral types of, in dogs less than 1 year of age, 28–31
quantitative analysis of, 22–24
paradigm shift created concerning, 12–13
seven steps from science to service in, 6–12
treatment of, case study of, 53–57
methods for evaluating, 45–57
definition of, 18–19, 20
drug-induced, prevalence of, 251–252
lodged in urethra, during voiding urohydropropulsion, management of, 287–289
medical shrinking of, prior to voiding urohydropropulsion, 286–287
naming of, 19
obstruction of urethra by, effectiveness of voiding urohydropropulsion during, 285–286
removal surgery, and voiding urohydropropulsion, time between, 290
struvite canine. See Struvite uroliths, canine.

Xanthine nephroliths, canine, 233
Xanthine uroliths, allopurinol-induced, 256–261
age, gender, and breed associated with, 256–257
diagnosis of, 258–260
etiopathogenesis of, 258
location of, 257
mineral composition and architecture of, 257
prevalence of, 256
prevention and treatment of, 260–261